Responses
Scientific Abstracts
Late breaking abstracts
New technologies in translational rheumatology
LB0002 A FIRST IN CLASS THERAPEUTIC NANOPARTICLE FOR SPECIFIC TARGETING OF ANTI-CITRULLINATED PROTEIN ANTIBODY AMELIORATES SERUM TRANSFER AND COLLAGEN INDUCED ARTHRITIS
Compose a Response to This Article
Other responses
No responses have been published for this article.